Drug Profile
HMR 1069
Alternative Names: 1069; HMR1069Latest Information Update: 17 Mar 2009
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class
- Mechanism of Action Guanylate cyclase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Angina pectoris
Most Recent Events
- 26 Feb 2009 Discontinued - Phase-I for Angina pectoris in France (unspecified route)
- 27 Apr 2005 This compound is still in active development
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis